Drug intelligence / Profile preview

theophylline + guaifenesin

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

Theophylline + guaifenesin is a combination oral medication used to treat or prevent symptoms of asthma, chronic bronchitis, and emphysema. Theophylline, a xanthine derivative, acts as a bronchodilator by relaxing smooth muscle in the airways and pulmonary vessels and suppressing airway responsiveness to irritants. Guaifenesin is an expectorant that helps thin and loosen mucus in the lungs, making it easier to cough up and clear airways. Together, these agents relieve cough, wheezing, and shortness of breath by improving airflow and mucus clearance[1][2][5][6].

Brand names: Ed-Bron GElixophyllin-GG
Other names: theophylline and guaifenesin

Targets

ADORA1 (Adenosine receptor A1 subtype)PDE (Phosphodiesterase family)ADORA2B (Adenosine A2B receptor)ADORA2A (Adenosine A₂A Receptor)

Beyond the preview

Go deeper on theophylline + guaifenesin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on theophylline + guaifenesin.

Explore the full profile